Jasper Therapeutics (NASDAQ:JSPR) vs. ADMA Biologics (NASDAQ:ADMA) Head-To-Head Survey

ADMA Biologics (NASDAQ:ADMA) and Jasper Therapeutics (NASDAQ:JSPR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ADMA Biologics and Jasper Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0	0	3	1	3.25
Jasper Therapeutics	0	0	10	0	3.00

ADMA Biologics presently has a consensus target price of $15.50, suggesting a potential downside of 14.32%. Jasper Therapeutics has a consensus target price of $73.00, suggesting a potential upside of 220.88%. Given Jasper Therapeutics’ higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than ADMA Biologics.

Risk & Volatility

ADMA Biologics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500.

Institutional & Insider Ownership

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by insiders. Comparatively, 2.7% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares ADMA Biologics and Jasper Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	10.53%	38.79%	17.35%
Jasper Therapeutics	N/A	-64.68%	-56.10%

Valuation & Earnings

This table compares ADMA Biologics and Jasper Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$258.21 million	16.33	-$28.24 million	($0.02)	-904.50
Jasper Therapeutics	N/A	N/A	-$64.46 million	($5.63)	-4.04

ADMA Biologics has higher revenue and earnings than Jasper Therapeutics. ADMA Biologics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

ADMA Biologics beats Jasper Therapeutics on 9 of the 14 factors compared between the two stocks.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

About Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.